Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals R&D Expense: 21.07M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ALNY R&D Expense Rankings
| Overall | 21st percentile | 1393 of 1764 |
| Sector | 20th percentile | 330 of 413 in Healthcare |
| Industry | 17th percentile | 124 of 150 in Biotechnology |
ALNY R&D Expense Range, Past 5 Years
| Minimum | 15.63M | Dec 2007 |
| Maximum | 59.58M | Sep 2007 |
| Average | 26.32M |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these ALNY related companies
ALNY News
Alnylam Pharma (ALNY) Reports Phase 1 Trial Results Show Proof of Concept for ALN-TTR01
May 10, 7:23AM Street Insider
May 10, 7:23AM Street Insider
Needham & Company Reiterates a 'Buy' on Alnylam Pharmaceuticals (ALNY); Focused on Development
May 04, 9:11AM Street Insider
May 04, 9:11AM Street Insider
Listen to $ALNY Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3f0z
about 24 days ago by earningscast
about 24 days ago by earningscast
Alnylam Pharmaceuticals, Inc. (ALNY) Posts Narrower than Expected Q1 Loss
May 03, 4:07PM Street Insider
May 03, 4:07PM Street Insider
Just closed out $GNTX $FCFS longs, $KMB $ALNY shorts for 5-day mkt neutral return of 3%!
about 26 days ago by TrendExhaustion
about 26 days ago by TrendExhaustion
Alnylam to Webcast Conference Call Discussing First Quarter 2012 Financial Results
Apr 26, 4:00PM Business Wire
Apr 26, 4:00PM Business Wire
Alnylam Elects Dr. Dennis Ausiello to its Board of Directors and Scientific Advisory Board
Apr 23, 8:00AM Business Wire
Apr 23, 8:00AM Business Wire
Listen to $ALNY at biocentury & thomson reuters future leaders in the biotech in - live at 10:00 AM, ondemand after - http://stks.co/3R0H
about 37 days ago by earningscast
about 37 days ago by earningscast
Alnylam (ALNY) Reports Statiscally Significant Data from ALN-PCS Phase I
Apr 20, 8:43AM Street Insider
Apr 20, 8:43AM Street Insider
Alnylam to Webcast Presentation at Future Leaders in the Biotech Industry Conference
Apr 13, 4:00PM Business Wire
Apr 13, 4:00PM Business Wire
Alnylam to Webcast Presentation at 11th Annual Needham Healthcare Conference
Mar 27, 4:00PM Business Wire
Mar 27, 4:00PM Business Wire
Alnylam Retains Key Claims for Kinesin Spindle Protein RNAi Patent in Interference Proceedings
Mar 14, 6:50AM Benzinga
Mar 14, 6:50AM Benzinga
Alnylam Retains Key Claims for Kinesin Spindle Protein (KSP) RNAi Patent in Interference Proceedings
Mar 14, 6:50AM Business Wire
Mar 14, 6:50AM Business Wire
Breakout candidate: $ARWR http://stks.co/2l0W Other RNAi companies: $ALNY $TKMR
about 79 days ago by Xatta_Trading
about 79 days ago by Xatta_Trading
Alnylam to Webcast Presentation at Barclays Capital Global Healthcare Conference
Mar 06, 4:00PM Business Wire
Mar 06, 4:00PM Business Wire
Alnylam to Webcast Presentation at Cowen and Company 32nd Annual Health Care Conference
Feb 29, 4:00PM Business Wire
Feb 29, 4:00PM Business Wire
$ALNY New 52 Week High - Crossed daily highs resistance. Next resistance 13.76 from 10/27/2010.
about 90 days ago by TradeIdeasQuant
about 90 days ago by TradeIdeasQuant
Market Wrap Video + Additions to Watch List http://stks.co/2RIw including: $ALNY $PXP $DMND $CRZO $NU
about 101 days ago by StockTiger
about 101 days ago by StockTiger
Market Wrap Video + Additions to Watch List http://stks.co/2Qqj including: $ALNY $PXP $DMND $CRZO $NU
about 102 days ago by StockTiger
about 102 days ago by StockTiger
Listen to $ALNY Q4 2011 earnings call (EPS -0.33 vs est -0.32) - live at 04:30 PM, ondemand after - http://stks.co/2Krr
about 108 days ago by earningscast
about 108 days ago by earningscast
$ALNY Reports Q4 EPS $(0.33) vs $(0.32) Est; Revenues $20.50M vs $20.90M Est
about 108 days ago by Benzinga
about 108 days ago by Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ALNY | 10.43 | +0.00 | +0.00% | 540.59M |
| ALN | 1.25 | -0.04 | -3.10% | 43.09M |
| ALLT | 23.89 | -0.31 | -1.28% | 714.79M |
| AMTD | 17.24 | +0.19 | +1.11% | 9.458B |
| AMTC | 0.1999 | +0.00 | +0.00% | 0.6797M |
| AMT | 65.75 | -0.10 | -0.15% | 25.89B |
| AMSWA | 8.00 | +0.01 | +0.13% | 210.72M |
| AMSG | 27.47 | -0.30 | -1.08% | 859.26M |
| AMSF | 27.18 | +0.08 | +0.30% | 493.32M |
| AMSC | 3.73 | -0.08 | -2.10% | 191.80M |
